Dossier assessment
Talazoparib (prostate cancer) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Talazoparib (prostate cancer) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Talazoparib (prostate cancer) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Indication:
Adults with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated
Result of dossier assessment:
- Patients with treatment-naive mCRPC without HRR mutation: hint of lesser benefit
- Patients with treatment-naive mCRPC with HRR mutation: added benefit not proven
- Patients with pretreated mCRPC: added benefit not proven
Project details
- Project no.
- A24-22
- Commission
- Commission awarded on 07.02.2024 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
- DOI
https://doi.org/10.60584/A24-22_en
Connected Projects
-
Dossier assessment
Talazoparib (breast cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed